Compared with Japanese patients with IDH1 WT GBM enrolled in the AVAglio control arm (no bevacizumab, hereafter the “control cohort”), there were no significant differences in OS or PFS in any expression subtypes, including the proneural subtype (Figure S5). The gene discussed is IDH1; the disease is glioblastoma.